147 related articles for article (PubMed ID: 38923548)
1. Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis.
Chompoopong P; Mauermann ML; Siddiqi H; Peltier A
Ann Neurol; 2024 Jun; ():. PubMed ID: 38923548
[TBL] [Abstract][Full Text] [Related]
2. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E; Kyriakides T
Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
[TBL] [Abstract][Full Text] [Related]
3. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
[TBL] [Abstract][Full Text] [Related]
4. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
[TBL] [Abstract][Full Text] [Related]
5. Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis.
Masuda T; Misumi Y; Nomura T; Yamakawa S; Tasaki M; Obayashi K; Ando Y; Ueda M
Muscle Nerve; 2024 Jan; 69(1):99-102. PubMed ID: 37960924
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
9. Neuromuscular amyloidosis: Unmasking the master of disguise.
Pinto MV; Dyck PJB; Liewluck T
Muscle Nerve; 2021 Jul; 64(1):23-36. PubMed ID: 33458861
[TBL] [Abstract][Full Text] [Related]
10. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Kessler L; Rischpler C; Malik RA; Herrmann K; Reinhardt HC; Rassaf T; Kleinschnitz C; Hagenacker T; Stettner M
J Neurol; 2023 Jul; 270(7):3483-3491. PubMed ID: 37014422
[TBL] [Abstract][Full Text] [Related]
11. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
12. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
13. Hereditary transthyretin amyloidosis overview.
Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.
Yamaguchi H; Kawahara H; Kodera N; Kumaki A; Tada Y; Tang Z; Sakai K; Ono K; Yamada M; Hanayama R
Front Mol Biosci; 2022; 9():839917. PubMed ID: 35402512
[TBL] [Abstract][Full Text] [Related]
15. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
16. [Amyloid neuropathy].
Ikegawa S
Rinsho Shinkeigaku; 1990 Dec; 30(12):1371-3. PubMed ID: 1966018
[TBL] [Abstract][Full Text] [Related]
17. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
Am J Kidney Dis; 2024 Mar; ():. PubMed ID: 38484868
[TBL] [Abstract][Full Text] [Related]
18. An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis.
Durmuş H; Çakar A; Demirci H; Alaylioglu M; Gezen-Ak D; Dursun E; Gülşen Parman Y
Acta Neurol Scand; 2021 Dec; 144(6):640-646. PubMed ID: 34322872
[TBL] [Abstract][Full Text] [Related]
19. Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights.
Koike H; Katsuno M
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30764529
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]